ImmunoGen Announces Conference Call to Discuss its Results for Six-Month Period and Quarter Ended December 31
January 25 2017 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Friday, February 17, 2017, to discuss ImmunoGen's
financial results for the six-month period and quarter ended
December 31, 2016. Management also will provide a brief update on
the business.
To access the live call by phone, dial 719-457-2627; the
conference ID is 4132697. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through March 3, 2017.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2
testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product,
Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170125006153/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen, Inc.Amy
Reilly, 781-895-0138amy.reilly@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657Robert.Stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024